Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

Startup Parabilis Medicines has raised $305 million in new funding, money that will help bring its lead drug for a variety of ...

TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.

The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that ...

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

US biotech Aktis Oncology has filed IPO documents with the Securities and Exchange Commission (SEC), in what could be the ...

After bringing on Eli Lilly and Co. as a major investor in its initial public offering, Aktis Oncology Inc. has scored proceeds of over $300 million the first Massachusetts IPO of 2026.

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are ...

Term Sheet readers sounded off on how they think the state of exits in the private markets will evolve through 2026.

Poplar Therapeutics Inc. launched on Wednesday capitalized with $50 million Series A financing and led by Chip Baird, the ...

China's biotech revival is pushing up prices of laboratory monkeys used in drug testing, as renewed R&D activity collides ...